5 completed. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 2 | Completed 2 |
Follow Replicor Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection REP 2139-Mg, Pegasys, Viread - Chronic Hepatitis B | Phase 2 | Completed | Replicor Inc. | 40 | 2016-03-01 | 2019-09-10 |
| REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection REP 2139-Ca + Pegasys (TM) - Chronic HBV Infection (HBeAg Negative) | Phase 2 | Completed | Replicor Inc. | 12 | 2014-09-01 | 2017-09-28 |
| Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B REP 2139-Ca, pegylated interferon, entecavir - Hepatitis B, Chronic | Phase 2 | Completed | Replicor Inc. | 5 | 2012-10-01 | 2019-05-08 |
| Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients REP 2139-Ca, Zadaxin, Pegasys - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Replicor Inc. | 12 | 2011-08-01 | 2016-01-05 |
| Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients REP 2055 - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Replicor Inc. | 8 | 2009-01-01 | 2016-01-05 |
peginterferon alfa-2a (3) · REP 2055 (1) · Tenofovir (1) · Thymalfasin (1) · entecavir (1)
Bangladesh (2) · Moldova (2)
Mamun Al-Mahtab, MD (3) · Victor Pantea, M.D. (1) · Victor Pantea, MD (1)
PMID 27257978, PMID 28964701, PMID 31323705, PMID 32147484, PMID 33553968, PMID 34558823